Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Reversal of Keloid Lesions
NCT04988022Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in keloid, sponsored by Icahn School of Medicine at Mount Sinai. Started May 2021; status: completed.
02
Drugs
03
Conditions
keloid
Beyond the preview
Go deeper on NCT04988022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988022.